MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7200
+0.0062
+0.87%
Opening 12:33 12/10 EST
OPEN
0.7100
PREV CLOSE
0.7138
HIGH
0.7300
LOW
0.7000
VOLUME
367.04K
TURNOVER
--
52 WEEK HIGH
2.000
52 WEEK LOW
0.3823
MARKET CAP
66.67M
P/E (TTM)
-2.4137
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TRVN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TRVN News

  • Trevena: Don't Get Hooked On This One
  • Seeking Alpha - Article.12/03 14:25
  • Trevena reports results from special population studies for oliceridine
  • Seeking Alpha - Article.11/20 13:37
  • Trevena +12% on positive oliceridine data
  • Seeking Alpha - Article.11/20 13:25
  • Trevena Announces Publication of Results from Special Population Studies for Oliceridine
  • GlobeNewswire.11/20 12:00

More

Industry

Biotechnology & Medical Research
+0.66%
Pharmaceuticals & Medical Research
+0.70%

Hot Stocks

Name
Price
%Change

About TRVN

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
More

Webull offers Trevena Inc (TRVN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.